As Merck’s Gardasil U.S. Sales Decline Profits Continue to Increase as Vaccine is Launched in China

Share it with your friends Like

Thanks! Share it with your friends!

Close

By AdminM

Gardasil-vaccine-China image

Health Impact News Editor Comments

The pharmaceutical marketing trade publication, Fierce Pharma, announced this month (May 2018) that Merck has beat Wall Street expectations for their Gardasil vaccine sales during the first quarter of 2018, achieving 24% growth with $660 million for the HPV vaccine.

The report notes that sales in the U.S. are declining, attributing the decline in sales to the CDC decision to reduce their recommendation of the Gardasil vaccine to be only two doses, instead of three.

Nothing is mentioned about declining public opinion regarding Gardasil, nor the numerous lawsuits against the company …read more

Source: Health Impact News

    

  • Rating:
  • Views:397 views
  • Categories: Health